LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa

Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gab...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouafo, Linda Chapdeleine Mekue, Péré, Hélène, Ndjoyi-Mbiguino, Angélique, Koyalta, Donato, Longo, Jean De Dieu, Mbopi-Kéou, François-Xavier, Kane, Coumba Toure, Bélec, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353127/
https://www.ncbi.nlm.nih.gov/pubmed/25767633
http://dx.doi.org/10.2174/1874613601509010009
_version_ 1782360560259563520
author Mouafo, Linda Chapdeleine Mekue
Péré, Hélène
Ndjoyi-Mbiguino, Angélique
Koyalta, Donato
Longo, Jean De Dieu
Mbopi-Kéou, François-Xavier
Kane, Coumba Toure
Bélec, Laurent
author_facet Mouafo, Linda Chapdeleine Mekue
Péré, Hélène
Ndjoyi-Mbiguino, Angélique
Koyalta, Donato
Longo, Jean De Dieu
Mbopi-Kéou, François-Xavier
Kane, Coumba Toure
Bélec, Laurent
author_sort Mouafo, Linda Chapdeleine Mekue
collection PubMed
description Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq(®) sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq(®) HIV-1 genotyping system for non-B subtypes HIV-1.
format Online
Article
Text
id pubmed-4353127
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-43531272015-03-12 LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa Mouafo, Linda Chapdeleine Mekue Péré, Hélène Ndjoyi-Mbiguino, Angélique Koyalta, Donato Longo, Jean De Dieu Mbopi-Kéou, François-Xavier Kane, Coumba Toure Bélec, Laurent Open AIDS J Article Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq(®) sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq(®) HIV-1 genotyping system for non-B subtypes HIV-1. Bentham Open 2015-02-27 /pmc/articles/PMC4353127/ /pubmed/25767633 http://dx.doi.org/10.2174/1874613601509010009 Text en © Mouafo et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Mouafo, Linda Chapdeleine Mekue
Péré, Hélène
Ndjoyi-Mbiguino, Angélique
Koyalta, Donato
Longo, Jean De Dieu
Mbopi-Kéou, François-Xavier
Kane, Coumba Toure
Bélec, Laurent
LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title_full LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title_fullStr LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title_full_unstemmed LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title_short LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
title_sort letter to the editor performance of the viroseq® hiv-1 genotyping system v2.0 in central africa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353127/
https://www.ncbi.nlm.nih.gov/pubmed/25767633
http://dx.doi.org/10.2174/1874613601509010009
work_keys_str_mv AT mouafolindachapdeleinemekue lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT perehelene lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT ndjoyimbiguinoangelique lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT koyaltadonato lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT longojeandedieu lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT mbopikeoufrancoisxavier lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT kanecoumbatoure lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica
AT beleclaurent lettertotheeditorperformanceoftheviroseqhiv1genotypingsystemv20incentralafrica

Ejemplares similares